Psoriasis therapy - Apollo Life SciencesAlternative Names: ALS-00T2-0501; Transdermal TNF blocker for psoriasis - Apollo Life Sciences
Latest Information Update: 09 Mar 2011
At a glance
- Originator Apollo Life Sciences
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 23 Jan 2006 Apollo Life Sciences has completed treatment in a phase Ib trial for Psorasis in Australia
- 18 Oct 2005 Phase-I clinical trials in Psoriasis in Australia (Transdermal)